Trial Profile
A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FER-IBD-MAIN
- Sponsors Vifor
- 26 Jun 2014 New trial record